News

West Pharmaceutical Services announced robust fourth-quarter and full-year 2025 financial results, driven by double-digit organic growth in high-value proprietary components, and introduced fiscal 2026 guidance projecting 4.6% to 6.5% reported net sales growth.

Read more...

Hong Kong-based Ascletis Pharma Inc. has selected its novel oral amylin receptor peptide agonist ASC36 for clinical development, planning an IND submission to the U.S. FDA in Q2 2026 for obesity treatment.

Read more...

Nearly a dozen mature biotech companies have formed the Midsized Biotech Alliance of America (MBAA) to protect their interests as the Trump administration advances drug pricing reforms.

Read more...

Aurobindo Pharma announced robust Q3FY26 results on February 10, 2026, with revenue up 8.4% to ₹8,646 crores, strong Europe growth, and key regulatory approvals for biosimilars through CuraTeQ Biologics.[4]

Read more...

The U.S. FDA has initiated its PreCheck pilot program to expedite construction and regulatory review of domestic drug manufacturing facilities, prioritizing critical medications.

Read more...

The European Medicines Agency has released its CHMP work plan for 2026, outlining key priorities for medicinal product evaluations and regulatory support across the EU pharmaceutical sector.

Read more...

U.S. pharmaceutical companies, including 16 with Trump administration pricing agreements, raised list prices on 872 brand-name medications with a median 4% increase in early 2026, highlighting ongoing pricing dynamics in the industry.[2]

Read more...

South Korean medtech firm Sky Labs has secured an exclusive deal with Japan's Otsuka Pharmaceutical to distribute its advanced ring-type blood pressure monitor CART BP pro in Japanese hospitals and clinics.

Read more...

Acadia Pharmaceuticals announced a negative trend vote from EMA's CHMP on its Marketing Authorization Application for trofinetide in treating Rett Syndrome, with plans to request re-examination.

Read more...

Bristol Myers Squibb has partnered with Microsoft to deploy FDA-cleared AI radiology tools via Precision Imaging Network, targeting earlier lung cancer detection in underserved U.S. communities.

Read more...